Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.

Fatma Nihan Akkoc MustafayevMihir Amitabh ShuklaAmanda LanierDenái R MiltonAngelica M GutierrezStephen K GruschkusJohn E Lewis Rashmi K Murthy Banu K Arun

Published in: Cancer (2023)

BRCA1/2 mutations occurred in 6.6% of patients with HER2/neu-positive BC and did not affect survival outcomes. Assessing the potential benefits of new treatment strategies, such as combining anti-HER2/neu therapies with poly(ADP-ribose) polymerase inhibitors, may lead to enhanced outcomes for these patients.

Keyphrases

positive breast cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
dna repair
risk assessment
oxidative stress
climate change
breast cancer risk
patient reported